EMA issues advice on use of REGN-COV2 antibody combination (casirivimab / imdevimab)
The CHMP has concluded that the monoclonal antibodies casirivimab and imdevimab can be used for the treatment of confirmed COVID-19 in patients who do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19.
Source:
European Medicines Agency
SPS commentary:
The review was undertaken to provide scientific opinion at EU level to support national decision making prior to marketing authorisation. Preliminary results indicate that the combination reduced the viral load (amount of virus in the back of the nose and throat) more than placebo (a dummy treatment) and led to fewer COVID-19-related medical visits.